Tags

Type your tag names separated by a space and hit enter

Serum biomarker profile orchestrating the seroconversion status of patients with autoimmune diseases upon planned primary 17DD Yellow fever vaccination.
Sci Rep. 2021 05 17; 11(1):10431.SR

Abstract

The present study aimed to investigate whether the serum biomarkers of immune response orchestrate the seroconversion status in patients with autoimmune diseases (AID) upon planned primary 17DD-YF vaccination. For this purpose a total of 161 individuals were enrolled in a prospective study, including patients with Rheumatoid Arthritis (RA = 38), Spondyloarthritis (SpA = 51), Systemic Lupus Erythematosus (SLE = 21) and Sjögren's Syndrome (SS = 30) along with a group of healthy controls (HC = 21). Analysis of plaque reduction neutralization test (PRNT) titers and seropositivity rates along with the 17DD-YF viremia and serum biomarkers were carried out at distinct time points (D0/D3-4/D5-6/D7/D14-28). The results demonstrated an overall lower PRNT titer and seropositivity rate (170 vs. 448; 77 vs. 95%) in AID as compared to HC, especially in SpA and SLE subgroups. No significant differences were observed in the viremia levels amongst groups. In general, a more prominent serum biomarker response was observed in AID as compared to HC, throughout the timeline kinetics. Remarkably, AID/PRNT(-) exhibited higher levels of several biomarkers at baseline as compared to AID/PRNT+. Moreover, while AID/PRNT(+) exhibited earlier increase in serum biomarkers at D3-4/D5-6, the AID/PRNT(-) displayed higher response at later time points (D7/D14-D28). Of note, a synchronic increase of IFN-γ at the peak of viremia (D5-6) was observed in HC and AID/PRNT(+) groups, whereas a later asynchronous IFN-γ response was reported for AID/PRNT(-) at D7. The biomarker profile tends to deflate at post-vaccination timeline, highlighting a putative immunomodulatory effect of live attenuated 17DD-YF vaccine in AID/PRNT(+), but not in AID/PRNT(-). Altogether these data suggested that inflammatory status prior vaccination, low IFN-γ at viremia peak and the occurrence of asynchronous biomarker storm after 17DD-YF vaccination may orchestrate the lack of neutralizing antibody response γ.

Authors+Show Affiliations

Grupo Integrado de Pesquisas Em Biomarcadores, Instituto René Rachou, Fundação Oswaldo Cruz (FIOCRUZ-Minas), Avenida Augusto de Lima 1715, Barro Preto, Belo Horizonte, MG, 30190-002, Brazil.Hospital Universitário Cassiano Antônio de Moraes, Universidade Federal Do Espírito Santo (UFES), Av. Mal. Campos, 1355, Santos Dumont, Vitória, ES, 29041-295, Brazil.Grupo Integrado de Pesquisas Em Biomarcadores, Instituto René Rachou, Fundação Oswaldo Cruz (FIOCRUZ-Minas), Avenida Augusto de Lima 1715, Barro Preto, Belo Horizonte, MG, 30190-002, Brazil.Grupo Integrado de Pesquisas Em Biomarcadores, Instituto René Rachou, Fundação Oswaldo Cruz (FIOCRUZ-Minas), Avenida Augusto de Lima 1715, Barro Preto, Belo Horizonte, MG, 30190-002, Brazil.Grupo Integrado de Pesquisas Em Biomarcadores, Instituto René Rachou, Fundação Oswaldo Cruz (FIOCRUZ-Minas), Avenida Augusto de Lima 1715, Barro Preto, Belo Horizonte, MG, 30190-002, Brazil.Instituto de Tecnologia Em Imunobiológicos (Bio-Manguinhos), Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, RJ, Brazil.Instituto de Tecnologia Em Imunobiológicos (Bio-Manguinhos), Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, RJ, Brazil.Instituto de Tecnologia Em Imunobiológicos (Bio-Manguinhos), Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, RJ, Brazil.Hospital Universitário Cassiano Antônio de Moraes, Universidade Federal Do Espírito Santo (UFES), Av. Mal. Campos, 1355, Santos Dumont, Vitória, ES, 29041-295, Brazil.Hospital Universitário Cassiano Antônio de Moraes, Universidade Federal Do Espírito Santo (UFES), Av. Mal. Campos, 1355, Santos Dumont, Vitória, ES, 29041-295, Brazil.Hospital Universitário Cassiano Antônio de Moraes, Universidade Federal Do Espírito Santo (UFES), Av. Mal. Campos, 1355, Santos Dumont, Vitória, ES, 29041-295, Brazil.Hospital Universitário Cassiano Antônio de Moraes, Universidade Federal Do Espírito Santo (UFES), Av. Mal. Campos, 1355, Santos Dumont, Vitória, ES, 29041-295, Brazil.Hospital Universitário Cassiano Antônio de Moraes, Universidade Federal Do Espírito Santo (UFES), Av. Mal. Campos, 1355, Santos Dumont, Vitória, ES, 29041-295, Brazil.Hospital Universitário Cassiano Antônio de Moraes, Universidade Federal Do Espírito Santo (UFES), Av. Mal. Campos, 1355, Santos Dumont, Vitória, ES, 29041-295, Brazil.Hospital Universitário Cassiano Antônio de Moraes, Universidade Federal Do Espírito Santo (UFES), Av. Mal. Campos, 1355, Santos Dumont, Vitória, ES, 29041-295, Brazil. Escola de Ciências da Saúde da Santa Casa de Misericórdia, Vitória, ES, Brazil.Hospital Universitário Cassiano Antônio de Moraes, Universidade Federal Do Espírito Santo (UFES), Av. Mal. Campos, 1355, Santos Dumont, Vitória, ES, 29041-295, Brazil.Hospital Universitário Cassiano Antônio de Moraes, Universidade Federal Do Espírito Santo (UFES), Av. Mal. Campos, 1355, Santos Dumont, Vitória, ES, 29041-295, Brazil.Hospital Universitário Cassiano Antônio de Moraes, Universidade Federal Do Espírito Santo (UFES), Av. Mal. Campos, 1355, Santos Dumont, Vitória, ES, 29041-295, Brazil.Hospital Universitário Cassiano Antônio de Moraes, Universidade Federal Do Espírito Santo (UFES), Av. Mal. Campos, 1355, Santos Dumont, Vitória, ES, 29041-295, Brazil.Hospital Universitário Cassiano Antônio de Moraes, Universidade Federal Do Espírito Santo (UFES), Av. Mal. Campos, 1355, Santos Dumont, Vitória, ES, 29041-295, Brazil.Hospital Universitário Cassiano Antônio de Moraes, Universidade Federal Do Espírito Santo (UFES), Av. Mal. Campos, 1355, Santos Dumont, Vitória, ES, 29041-295, Brazil.Hospital Universitário Cassiano Antônio de Moraes, Universidade Federal Do Espírito Santo (UFES), Av. Mal. Campos, 1355, Santos Dumont, Vitória, ES, 29041-295, Brazil.Escola de Ciências da Saúde da Santa Casa de Misericórdia, Vitória, ES, Brazil.Centro de Referências Para Imunobiológicos Especiais (CRIE) da Secretaria de Saúde Do Estado Do Espírito Santo, Vitória, ES, Brazil.Departamento de Vigilância das Doenças Transmissíveis, Secretaria de Vigilância Em Saúde, Ministério da Saúde, Brasília, DF, Brazil.Faculdade de Ciências da Saúde de Barretos - FACISB, Barretos, SP, Brazil.Programa de Pós Graduação Em Ciências Médicas, Faculdade de Medicina, Serviço de Reumatologia Do Hospital Universitário de Brasília, Universidade de Brasília, Brasília, DF, Brazil.Hospital Universitário Cassiano Antônio de Moraes, Universidade Federal Do Espírito Santo (UFES), Av. Mal. Campos, 1355, Santos Dumont, Vitória, ES, 29041-295, Brazil. val.valim@gmail.com.Grupo Integrado de Pesquisas Em Biomarcadores, Instituto René Rachou, Fundação Oswaldo Cruz (FIOCRUZ-Minas), Avenida Augusto de Lima 1715, Barro Preto, Belo Horizonte, MG, 30190-002, Brazil. oamfilho@gmail.com.

Pub Type(s)

Journal Article
Observational Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

34001945

Citation

da Costa-Rocha, Ismael Artur, et al. "Serum Biomarker Profile Orchestrating the Seroconversion Status of Patients With Autoimmune Diseases Upon Planned Primary 17DD Yellow Fever Vaccination." Scientific Reports, vol. 11, no. 1, 2021, p. 10431.
da Costa-Rocha IA, Machado KLLL, Campi-Azevedo AC, et al. Serum biomarker profile orchestrating the seroconversion status of patients with autoimmune diseases upon planned primary 17DD Yellow fever vaccination. Sci Rep. 2021;11(1):10431.
da Costa-Rocha, I. A., Machado, K. L. L. L., Campi-Azevedo, A. C., Teixeira-Carvalho, A., Peruhype-Magalhães, V., de Lima, S. M. B., Miranda, E. H., Trindade, G. F., Casagrande, T. Z., Miyamoto, S. T., Deotti, S. C., Barbosa, R. V. R., Rocha, P. C. M., Serrano, E. V., Dinis, V. G., Gouvêa, S. A., Gavi, M. B. R. O., da Silva, L. B., Duque, R. H., ... Martins-Filho, O. A. (2021). Serum biomarker profile orchestrating the seroconversion status of patients with autoimmune diseases upon planned primary 17DD Yellow fever vaccination. Scientific Reports, 11(1), 10431. https://doi.org/10.1038/s41598-021-89770-8
da Costa-Rocha IA, et al. Serum Biomarker Profile Orchestrating the Seroconversion Status of Patients With Autoimmune Diseases Upon Planned Primary 17DD Yellow Fever Vaccination. Sci Rep. 2021 05 17;11(1):10431. PubMed PMID: 34001945.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Serum biomarker profile orchestrating the seroconversion status of patients with autoimmune diseases upon planned primary 17DD Yellow fever vaccination. AU - da Costa-Rocha,Ismael Artur, AU - Machado,Ketty Lysie Libardi Lira, AU - Campi-Azevedo,Ana Carolina, AU - Teixeira-Carvalho,Andréa, AU - Peruhype-Magalhães,Vanessa, AU - de Lima,Sheila Maria Barbosa, AU - Miranda,Emily Hime, AU - Trindade,Gisela Freitas, AU - Casagrande,Thays Zanon, AU - Miyamoto,Samira Tatiyama, AU - Deotti,Sávio Carvalho, AU - Barbosa,Rafaela Villa Real, AU - Rocha,Priscila Costa Martins, AU - Serrano,Erica Vieira, AU - Dinis,Valquiria Garcia, AU - Gouvêa,Sônia Alves, AU - Gavi,Maria Bernadete Renoldi de Oliveira, AU - da Silva,Lidia Balarini, AU - Duque,Ruben Horst, AU - Gianordoli,Ana Paula Espíndula, AU - Bissoli,Maria de Fatima, AU - Gouvea,Maria da Penha Gomes, AU - Pinto-Neto,Lauro Ferreira da Silva, AU - Burian,Ana Paula Neves, AU - Fantinato,Francieli Fontana Sutile Tardetti, AU - Pileggi,Gecilmara Salviato, AU - da Mota,Licia Maria Henrique, AU - Valim,Valéria, AU - Martins-Filho,Olindo Assis, Y1 - 2021/05/17/ PY - 2020/12/14/received PY - 2021/04/30/accepted PY - 2021/5/18/entrez PY - 2021/5/19/pubmed PY - 2021/5/19/medline SP - 10431 EP - 10431 JF - Scientific reports JO - Sci Rep VL - 11 IS - 1 N2 - The present study aimed to investigate whether the serum biomarkers of immune response orchestrate the seroconversion status in patients with autoimmune diseases (AID) upon planned primary 17DD-YF vaccination. For this purpose a total of 161 individuals were enrolled in a prospective study, including patients with Rheumatoid Arthritis (RA = 38), Spondyloarthritis (SpA = 51), Systemic Lupus Erythematosus (SLE = 21) and Sjögren's Syndrome (SS = 30) along with a group of healthy controls (HC = 21). Analysis of plaque reduction neutralization test (PRNT) titers and seropositivity rates along with the 17DD-YF viremia and serum biomarkers were carried out at distinct time points (D0/D3-4/D5-6/D7/D14-28). The results demonstrated an overall lower PRNT titer and seropositivity rate (170 vs. 448; 77 vs. 95%) in AID as compared to HC, especially in SpA and SLE subgroups. No significant differences were observed in the viremia levels amongst groups. In general, a more prominent serum biomarker response was observed in AID as compared to HC, throughout the timeline kinetics. Remarkably, AID/PRNT(-) exhibited higher levels of several biomarkers at baseline as compared to AID/PRNT+. Moreover, while AID/PRNT(+) exhibited earlier increase in serum biomarkers at D3-4/D5-6, the AID/PRNT(-) displayed higher response at later time points (D7/D14-D28). Of note, a synchronic increase of IFN-γ at the peak of viremia (D5-6) was observed in HC and AID/PRNT(+) groups, whereas a later asynchronous IFN-γ response was reported for AID/PRNT(-) at D7. The biomarker profile tends to deflate at post-vaccination timeline, highlighting a putative immunomodulatory effect of live attenuated 17DD-YF vaccine in AID/PRNT(+), but not in AID/PRNT(-). Altogether these data suggested that inflammatory status prior vaccination, low IFN-γ at viremia peak and the occurrence of asynchronous biomarker storm after 17DD-YF vaccination may orchestrate the lack of neutralizing antibody response γ. SN - 2045-2322 UR - https://www.unboundmedicine.com/medline/citation/34001945/Serum_biomarker_profile_orchestrating_the_seroconversion_status_of_patients_with_autoimmune_diseases_upon_planned_primary_17DD_Yellow_fever_vaccination_ L2 - https://doi.org/10.1038/s41598-021-89770-8 DB - PRIME DP - Unbound Medicine ER -